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In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC7) characterized adults, not taking anti-
hypertensive medication, with systolic blood pressure (SBP) 
between 120 and 139 mm Hg with diastolic blood pressure 
(DBP) <90 mm Hg or DBP between 80 and 89 mm Hg with 
SBP <140 mm Hg as having prehypertension.1 Adults with 
prehypertension have a high risk for developing hypertension, 
defined as SBP ≥140 mm Hg or DBP ≥90 mm Hg or the use 
of antihypertensive medication.2–5 The risk for hypertension 
among people with prehypertension can be reduced through 
lifestyle modification and antihypertensive medication use.1,5–7 
While one goal of the JNC7 guideline was to increase aware-
ness of the high risk for incident hypertension associated with 
prehypertension,1,7 studies conducted after its publication have 
been cross-sectional, and there have been limited data pub-
lished on the temporal changes in the prevalence of prehyper-
tension and the risk factors for incident hypertension among 
those with prehypertension.8–11
In the current study, we determined temporal changes in the 
prevalence of prehypertension among US adults, overall, and 
within subgroups defined by age, race/ethnicity, and sex. Also, 
because there is an opportunity to prevent the transition to hyper-
tension and reduce cardiovascular disease (CVD) morbidity and 
mortality through lifestyle modification and pharmacological 
antihypertensive treatment among adults with prehypertension, 
temporal changes in risk factors for incident hypertension, tar-
get-organ damage, and CVD were determined among this popu-
lation.12 Results from the current study may help to determine 
the need for interventions among adults with prehypertension 
and identify specific approaches that may lower blood pressure 
(BP) in adults at high risk for developing hypertension.
Methods
Study Population
The National Health and Nutrition Examination Survey (NHANES) 
is a US-based cross-sectional survey of the noninstitutionalized 
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civilian population. NHANES applies a multistage, stratified, prob-
ability sampling approach to identify participants and allows the gen-
eration of nationally representative estimates. Additional information 
on the design and conduct of NHANES is available online.13 In brief, 
NHANES has been conducted in 2-year cycles since 1999. For the 
current analysis, we studied seven 2-year cycles from 1999–2000 
through 2011–2012.14 During this time period, there were 30 958 par-
ticipants with 3 valid clinic SBP and DBP measurements and com-
plete information on antihypertensive medication use obtained during 
study visits (Figure S1 in the online-only Data Supplement). The 
National Center for Health Statistics Review Board governing human 
subjects’ research approved the NHANES protocol. All participants 
provided written informed consent.
Data Collection
NHANES data were collected during an in-home interview and clinic 
examination. During the interview, trained staff administered ques-
tionnaires to collect self-reported information on sociodemographics, 
diet- and health-related behaviors and prior diagnosed comorbid con-
ditions, and use of prescription antihypertensive medication. During 
the clinic examination, trained technicians measured height, weight, 
and BP and collected blood and spot urine samples.
Risk Factors for Incident Hypertension, CVD, 
and Target-Organ Damage
Age was categorized as <40, 40 to 59, and ≥60 years. Race/ethnic-
ity was defined as non-Hispanic white, non-Hispanic black, and 
Hispanic. Heart rate, quantified in beats per minutes, was measured 
by palpating the radial pulse after 3 minutes of rest. Total choles-
terol was categorized as normal (<200 mg/dL), borderline elevated 
(200–239 mg/dL), or elevated (≥240 mg/dL). Low levels of high-
density-lipoprotein cholesterol were defined as <40 and <50 mg/dL 
in men and women, respectively. C-reactive protein was defined as 
normal (<1 mg/L), borderline elevated (1 to <3 mg/L), or elevated 
(≥3 mg/L). Participants were categorized as not having prediabetes 
or diabetes mellitus if they did not self-report a prior diagnosis by a 
physician and were not taking hypoglycemic medication, and they 
had a hemoglobin A1C <5.7% prediabetes if they did not self-report 
a history of diabetes mellitus and were not taking hypoglycemic 
medication and had hemoglobin A1C of 5.7% to 6.4% or diabetes 
mellitus if they self-reported a history of diagnosis or were taking 
hypoglycemic medication or had hemoglobin A1C ≥6.5%. Estimated 
glomerular filtration rate was calculated using the CKD-EPI (chronic 
kidney disease epidemiology collaboration) equation with calibrated 
serum creatinine.15,16 Reduced estimated glomerular filtration rate 
was defined as <60 mL/min/1.73 m2. Elevated urinary albumin-to-
creatinine ratio was defined as ≥30 mg/g. High 10-year predicted ath-
erosclerotic CVD risk was defined as ≥7.5% using the pooled cohort 
risk equations.17
Modifiable Lifestyle Risk Factors
Body mass index, calculated as weight in kilograms divided by height 
in meters squared, was categorized as <25, 25 to <30, and ≥30 kg/
m2. Current cigarette smoking was defined by self-reporting smoking 
>100 cigarettes in their lifetime and currently smoking or having quit 
<1 year ago. Leisure-time physical activity was calculated in minutes 
per week following similar methods as described by Ladabaum et 
al.18 Briefly, the total minutes of physical activity per week were cal-
culated from participants’ self-reported information on the frequency, 
duration, and level of exertion for leisure-time activities. The ideal 
physical activity category included participants who self-reported 
at least 75 minutes of vigorous activity or at least 150 minutes of 
moderate or vigorous activity per week. The category for interme-
diate physical activity included those who had 1 to 74 minutes of 
vigorous activity or 1 to 149 minutes of moderate or vigorous activity 
per week. Poor physical activity was defined as 0 minutes of mod-
erate or vigorous activity per week. Weekly alcohol consumption, 
determined by the self-reported number of drinks per week during 
the previous 12 months, was defined as none, moderate (men: 1–14 
drinks; women: 1–7 drinks), or heavy (men: >14 drinks; women: >7 
drinks). Interviewer-administered questionnaires were used to record 
dietary intake during two 24-hour periods. A Dietary Approaches to 
Stop Hypertension (DASH) adherence score was estimated similar 
to the studies by Fung et al19 and Günther et al.20 This dietary pattern 
is low in sodium and cholesterol, high in dietary fiber, potassium, 
calcium, and magnesium, and moderately high in protein content. 
Quintiles of the 8 DASH diet components (increased intake of fruits, 
vegetables, low-fat dairy products, whole grains, and nuts/seeds/
legumes; reduced intake of fats/oils, sugar-sweetened beverages, and 
meat/poultry/fish) and reduced sodium consumption were created 
among all NHANES participants between 1999 and 2012. The rank 
scores were summed to obtain an overall DASH diet score (range: 
9 [least healthy] to 45 [healthiest]). Participants were grouped into 
quartiles based on the distribution of DASH diet scores among all US 
adults ≥20 years of age (cut points [quartile 1 to quartile 4]: <25 [least 
healthy], 25 to <28, 28 to <31, and ≥31 [healthiest]).
Blood Pressure
BP was measured following a standardized protocol using the 
American Heart Association’s recommendations.13,21–23 After par-
ticipants were seated for at least 5 minutes in an upright position 
with their back and arms supported, feet flat on the floor, and legs 
uncrossed, trained staff conducted 3 BP measurements in the right 
arm using a mercury sphygmomanometer, and appropriate cuff size 
determined from an arm circumference measurement. At least 30 
seconds elapsed between the measurements. Quality control included 
quarterly recertification with retraining as needed, annually retraining 
of all physicians and monitoring/repairing equipment. Certification 
required video test recognition of Korotkoff sounds and perform-
ing measurements on volunteers. Normal BP was defined as SBP 
<120 and DBP <80 mm Hg without antihypertensive medication use. 
Prehypertension was defined by SBP of 120 to 139 mm Hg with DBP 
<90 mm Hg or DBP of 80 to 89 mm Hg with SBP <140 mm Hg with-
out antihypertensive medication use. The lower range of prehyperten-
sion was defined as SBP 120 to 129 mm Hg with DBP <85 mm Hg or 
DBP 80 to 84 mm Hg with SBP <130 mm Hg, and the upper range of 
prehypertension was defined as SBP 130 to 139 mm Hg or DBP 85 
to 89 mm Hg. Hypertension was defined as SBP ≥140 or DBP ≥90 
mm Hg or antihypertensive medication use.
Statistical Analysis
The age-adjusted percentage of US adults ≥20 years of age with nor-
mal BP, prehypertension, and hypertension was calculated for each 
2-year cycle of NHANES overall and in subgroups defined by age, 
race/ethnicity, and sex. Age was adjusted using 2010 US census data. 
Using logistic regression, the statistical significance of the linear 
trend in the age-adjusted prevalence of prehypertension was calcu-
lated by modeling an ordinal variable for each NHANES cycle as a 
continuous predictor variable of prehypertension status. Differences 
in linear trends in the prevalence of prehypertension over NHANES 
cycles across age, race/ethnicity, and sex subgroups were determined 
by modeling interaction terms (eg, sex×NHANES cycle). Analyses 
were repeated to calculate the age-adjusted prevalence of prehyper-
tension among adults without normal BP (ie, among adults with pre-
hypertension or hypertension) and without hypertension (ie, among 
adults with normal BP and prehypertension), separately. Also, mul-
tivariable adjusted prevalence ratios for prehypertension associated 
with NHANES cycles were calculated among adults without normal 
BP and without hypertension, separately, using Poisson regression. 
An initial model with adjustment for age, race/ethnicity, and sex was 
further adjusted for incident hypertension, CVD and target-organ 
damage, and modifiable lifestyle risk factors in 3 subsequent regres-
sion models. Pooling 2009 to 2012 NHANES data to provide stable 
estimates, we calculated prevalence ratios for prehypertension or 
hypertension comparing participants <40 and 40 to 59 years of age 
versus ≥60 years of age, non-Hispanic blacks and Hispanics versus 
non-Hispanic whites, and females versus males using log-binomial 
models. Prevalence ratios for prehypertension associated with age, 
race/ethnicity, and sex were also calculated among US adults without 
hypertension.
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The mean or prevalence of risk factors (ie, heart rate, total choles-
terol, high-density-lipoprotein cholesterol, diabetes mellitus, estimat-
ed glomerular filtration rate, urinary albumin-to-creatinine ratio, and 
10-year predicted atherosclerotic CVD risk) and modifiable lifestyle 
factors (ie, body mass index, smoking status, physical activity level, 
alcohol consumption, and DASH diet adherence) was calculated in 
adults with prehypertension by NHANES cycle. The statistical sig-
nificance of trends in the change in risk factors over NHANES cycles 
was calculated using linear regression or logistic regression, as ap-
propriate. All analyses were performed accounting for the complex 
survey design of NHANES, and results were weighted to the non-
institutionalized civilian US adult population using SAS 9.4 (SAS 
Institute, Cary, NC). Two-sided P values <0.05 were considered sta-
tistically significant.
Results
Trends in Prevalent Normal BP, Prehypertension, 
and Hypertension
From 1999–2000 to 2011–2012, there was a nonstatisti-
cally significant increase in the age-adjusted percentage of 
US adults with normal BP and hypertension and a statisti-
cally significant decrease in prevalent prehypertension from 
31.2% to 28.2% (Figure 1, top). The number of US adults 
with normal BP and hypertension increased from 1999–
2000 and 2011–2012, whereas the number with prehyper-
tension was stable (Figure 1, bottom). The prevalence of 
normal BP increased (Figure 2, left; Table S1, top) and pre-
hypertension decreased in those ≥60 years of age between 
1999–2000 and 2011–2012. A decrease in the age-adjusted 
prevalence of prehypertension occurred among men (Figure 
2, middle; Table S1, middle). The prevalence of hyperten-
sion remained stable in all subgroups (Figure 2, right; Table 
S1, bottom).
Trends in Prevalent Prehypertension Among Adults 
Without Normal BP and Without Hypertension
Among US adults without normal BP, the age-adjusted preva-
lence of prehypertension decreased between 1999–2000 and 
2011–2012. There was no change in prehypertension in any 
of the age categories investigated, but the prevalence of pre-
hypertension declined in non-Hispanic whites, non-Hispanic 
blacks, and males (Figure 3, left; Table S2, top). The change 
in the prevalence of prehypertension from 1999–2000 and 
2011–2012 was similar across age, race/ethnicity, and sex 
groups. In adults without hypertension, there was a decrease 
in the prevalence of prehypertension overall and among US 
adults ≥60 years of age and males, but no statistically signifi-
cant change was present for any of the race/ethnicity groups 
(Figure 3, right; Table S2, bottom).
Among US adults without normal BP, there was a non-
statistically significant decrease in the prevalence ratio of 
prehypertension between 1999–2000 and 2011–2012 after 
adjustment for age, race/ethnicity, and sex (Table 1, top). There 
was no trend in the prevalence ratios for prehypertension after 
Figure 1. Age-adjusted percentage (top) and unadjusted number (bottom) of US adults ≥20 y of age with normal blood pressure, 
prehypertension, and hypertension by National Health and Nutrition Examination Survey by calendar year. Normal blood pressure: systolic 
blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg without antihypertensive medication use. Prehypertension: systolic 
blood pressure 120 to 139 mm Hg with diastolic blood pressure <90 mm Hg or diastolic blood pressure 80 to 89 mm Hg with systolic 
blood pressure <140 mm Hg without antihypertensive medication use. Hypertension: systolic blood pressure ≥140 mm Hg or diastolic 
blood pressure ≥90 mm Hg and antihypertensive medication use.
278  Hypertension  August 2017
further adjustment for risk factors for incident hypertension, 
CVD and target-organ damage, and modifiable lifestyle risk 
factors. The prevalence ratio for prehypertension decreased 
over calendar time among US adults without hypertension 
(Table 1, bottom).
Prevalence of Prehypertension and Hypertension 
in Subgroups of US Adults
In 2009 through 2012, after race/ethnicity and sex adjust-
ment, US adults <40 and 40 to 59 versus ≥60 years of age 
were less likely to have prehypertension or hypertension ver-
sus normal BP (Table S3, middle). After age and sex adjust-
ment, the prevalence ratio for prehypertension or hypertension 
versus normal BP was higher for non-Hispanic blacks versus 
non-Hispanic whites. After age and race/ethnicity adjustment, 
females were less likely to have prehypertension or hyperten-
sion compared with males. Among adults without hyperten-
sion and after race/ethnicity and sex adjustment, US adults 40 
to 59 and ≥60 years of age were less likely than their coun-
terparts <40 years of age to have prehypertension (Table S3, 
right). Also, non-Hispanic blacks were more likely than non-
Hispanic whites, and females were less likely than males to 
have prehypertension.
Modifiable Risk Factors Among Adults With 
Prehypertension
Among US adults with prehypertension, mean heart rate and 
the prevalence of prediabetes and diabetes mellitus increased 
and elevated total cholesterol decreased between 1999–2000 
and 2011–2012 (Table 2). Also, while the proportion of adults 
who were overweight or obese increased, DASH diet adher-
ence decreased during the study period (Table 3). There was 
also a nonstatistically significant increase in poor levels of 
leisure-time physical activity among adults with prehyperten-
sion. In contrast, the prevalence of current smoking declined 
from 25.9% to 23.2% (P trend=0.097). Heavy alcohol intake 
did not change over time.
Discussion
Between 1999–2000 and 2011–2012, there was a statistically 
significant decrease in the age-adjusted prevalence of prehy-
pertension and nonstatistically significant increase in normal 
BP and hypertension. The number of US adults with prehyper-
tension remained stable, whereas the number with normal BP 
and hypertension increased during this time period because 
of population growth. The prevalence of normal BP increased 
in those ≥60 years of age; prehypertension decreased in those 
≥60 years of age, non-Hispanic whites, non-Hispanic blacks, 
and males; and hypertension increased in non-Hispanic 
whites, non-Hispanic, blacks, and males. Also, among adults 
with prehypertension, mean heart rate and the proportion with 
prediabetes and diabetes mellitus and who were overweight 
and obese increased between 1999–2000 and 2011–2012. In 
contrast, adherence to the DASH diet-eating pattern decreased 
during this time period. There was a nonstatistically signifi-
cant increase in poor levels of leisure-time physical activity 
and a nonstatistically significant decrease in current smoking 
over time.
Figure 2. Age-adjusted percentage of US adults ≥20 y of age with normal blood pressure (left), prehypertension (middle), and 
hypertension (right) from 1999–2000 and 2011–2012 by age, race/ethnicity, and sex. Arrows indicate the prevalence corresponding with 
non-Hispanic whites, non-Hispanic blacks, or Hispanics where the plotted values for these race/ethnic groups are difficult to distinguish. 
The age-adjusted percentage of US adults ≥20 y of age with normal blood pressure, prehypertension, and hypertension from 1999–2000 
and 2011–2012 overall is reported in Table S1. Also, the 95% confidence interval corresponding with each point estimate in the current 
figure, P trend representing the change in the prevalence over calendar period and the P interaction representing differences in the 
change in the prevalence during calendar period across age, race/ethnicity, and sex subgroups is reported in Table S1. NHANES indicates 
National Health and Nutrition Examination Survey.
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Temporal changes in the proportion of US adults with 
hypertension have been studied more often than prehyperten-
sion. NHANES data indicate the age-adjusted prevalence of 
hypertension increased from 23.9% (95% confidence inter-
val [CI], 22.7%–25.2%) in 1988–1994 to 28.5% (95% CI, 
25.9%–31.3%) in 1999–2000 and remained stable through 
2007–2008 at 29.5% (95% CI, 27.6%–30.5%).24 The results 
reported herein also indicate that the prevalence of hyperten-
sion has not changed substantially since 1999–2000. Because 
hypertension is a lifelong condition, reducing the prevalence 
of hypertension will require interventions to prevent its 
development.
A study from 1939 described SBP levels between 120 and 
139 mm Hg as the “danger zone” for progressing to incident 
hypertension and CVD in younger individuals.25 The goal of 
the JNC7 for defining prehypertension was to increase aware-
ness so that individuals with this condition can delay or pre-
vent incident hypertension through early adoption of healthy 
lifestyle interventions that lower BP levels and reduce CVD 
risk.1 The range of BP levels used to define prehypertension 
was determined from accumulating evidence indicating that 
these levels were associated with traditional CVD risk factors 
(eg, obesity, diabetes mellitus), incident hypertension, and 
cardiovascular morbidity and mortality.1,7,26–30
While evidence from randomized controlled trials (RCTs) 
indicates that prophylactic antihypertensive medication reduces 
BP and the incidence of hypertension, the JNC7 emphasized 
utilization of healthy lifestyles for individuals with prehyper-
tension.1,31,32 The trials of hypertension prevention reported that 
a mean 7.7 pounds difference in weight loss during 18 months 
in the active intervention (ie, weight loss counseling) versus 
control group resulted in 5.8/3.2 mm Hg lower SBP/DBP lev-
els.33 A meta-analysis of 27 RCTs demonstrated that partici-
pants randomized to aerobic exercise had a 4 mm Hg (95% CI, 
2.75–5.32) reduction in SBP compared with their counterparts 
randomized to control groups, independent of the exercise 
Figure 3. Age-adjusted percentage of US adults ≥20 y of age with prehypertension in US adults without normal blood pressure (left) 
and without hypertension (right) by National Health and Nutrition Examination Survey calendar year overall and by age, race/ethnicity, 
and sex. Arrows indicate the prevalence corresponding with non-Hispanic whites, non-Hispanic blacks, or Hispanics where the plotted 
values for these race/ethnic groups are difficult to distinguish. The 95% confidence interval corresponding with each point estimate, P-
trend representing the change in the prevalence over calendar period and the P interaction representing differences in the change in the 
prevalence over calendar period across age, race/ethnicity, and sex subgroups is reported in Table S2. NHANES indicates National Health 
and Nutrition Examination Survey.
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intensity level.34 RCTs also provide evidence that a diet low in 
sodium, high in potassium, rich with fruits and vegetables, and 
with reduced saturated and total fat from dairy products can 
reduce SBP.35,36 For example, randomization to the DASH with 
a low sodium level compared with a control diet with compara-
tively higher amounts of sodium reduced SBP by 7.1 mm Hg in 
adults without hypertension.35 Furthermore, in a meta-analysis 
of 6 RCTs, reducing alcohol intake in adults without hyperten-
sion by 75% to 100% compared with baseline has been dem-
onstrated to lower SBP by 3.6 (95% CI, 2.5–4.6) mm Hg and 
DBP by 1.8 (95% CI, 0.6–3) mm Hg.37 While each of these 
interventions is beneficial for reducing BP, the PREMIER and 
MRFIT (Multiple Risk Factor Intervention Trial) RCTs pro-
vided evidence of an additive effect of increasing the number 
of lifestyle interventions to lower BP levels.6,38,39 In the current 
analysis, many US adults with prehypertension had risk fac-
tors for incident hypertension, target-organ damage, and CVD 
and were not using lifestyle interventions. Importantly, low-
cost interventions for preventing hypertension are proven in all 
age groups, race/ethnicities, and males and females.6 This indi-
cates there is a substantial opportunity to lower the incidence 
of hypertension and CVD through lifestyle changes. However, 
novel approaches for maintaining lifestyle modification may 
be needed because body mass index and diabetes mellitus 
increased, and there was a decline in adherence to the DASH 
diet between 1999–2000 and 2011–2012.
Few studies have reported the number of US adults with 
normal BP, prehypertension, and hypertension over time. In 
the current study, the percentage of US adults with normal BP 
and hypertension was stable, and the proportion who had pre-
hypertension increased between 1999–2000 and 2011–2012. 
However, the number of US adults with normal BP and hyper-
tension increased, and the number with prehypertension was 
stable during the time period. This suggests that the popula-
tion growth has been primarily among US adults with normal 
BP and hypertension rather than with prehypertension.
The current study has several strengths. These include the 
complex sampling design of NHANES that permitted the calcu-
lation of prevalence estimates for the US population. The large 
sample size of NHANES facilitated subgroup analyses. Also, 
NHANES follows protocols that facilitate the rigorous collec-
tion of study data, including BP. However, the results should be 
interpreted in the context of known and potential limitations. 
Mean BP levels were calculated from measurements at a single 
examination. Average BP measured at multiple exams would 
provide more accurate information to categorize participants 
by their BP level. Participants in NHANES were not followed 
longitudinally, which prevented the assessment of within-per-
son changes in BP levels, risk factors for incident hypertension, 
target-organ damage and CVD, and modifiable lifestyle risk 
factors at the individual level. Data for Asian adults, separately 
from other race/ethnicity groups, were not available for the 
NHANES calendar years of 1999–2000 through 2009–2010, 
and temporal changes could not be reported for this subgroup.
Perspectives
The current serial cross-sectional analysis of NHANES data 
reports that the age-adjusted prevalence of prehypertension 
decreased among US adults between 1999–2000 and 2011–
2012. During this time period, the age-adjusted proportion of 
US adults with normal BP and hypertension remained stable. 
Also, there has been limited improvement in risk factors for 
Table 1. Multivariable Adjusted Prevalence Ratio for Prehypertension Among US Adults ≥20 Y of Age Without Normal Blood 
Pressure and Without Hypertension by National Health and Nutrition Examination Survey Calendar Year
Model
National Health and Nutrition Examination Survey Calendar Year
P Trend*1999–2000 2001–2002 2003–2004 2005–2006 2007–2008 2009–2010 2011–2012
 Prevalence ratio (95% confidence interval)
Prehypertension among US adults ≥20 y of age without normal blood pressure
Model 1 1 (reference) 0.99 (0.91–1.09) 0.95 (0.86–1.04) 0.95 (0.86–1.04) 0.93 (0.85–1.01) 0.92 (0.83–1.01) 0.95 (0.87–1.05) 0.052
Model 2 1 (reference) 1.00 (0.91–1.09) 0.94 (0.86–1.02) 0.95 (0.87–1.03) 0.94 (0.87–1.01) 0.92 (0.84–1.00) 0.96 (0.88–1.05) 0.087
Model 3 1 (reference) 1.01 (0.93–1.10) 0.94 (0.87–1.03) 0.97 (0.89–1.06) 0.95 (0.88–1.03) 0.96 (0.87–1.06) 0.99 (0.91–1.08) 0.474
Model 4 1 (reference) 1.02 (0.93–1.10) 0.95 (0.88–1.03) 0.98 (0.90–1.07) 0.95 (0.88–1.03) 0.98 (0.89–1.07) 1.00 (0.91–1.10) 0.678
Prehypertension among US adults ≥20 y of age without hypertension
Model 1 1 (reference) 0.94 (0.84–1.05) 0.91 (0.82–1.03) 0.91 (0.80–1.03) 0.91 (0.81–1.02) 0.84 (0.75–0.94) 0.92 (0.82–1.03) 0.032
Model 2 1 (reference) 0.92 (0.83–1.02) 0.89 (0.79–1.00) 0.90 (0.80–1.03) 0.89 (0.80–0.99) 0.84 (0.75–0.94) 0.92 (0.82–1.04) 0.072
Model 3 1 (reference) 0.93 (0.84–1.03) 0.88 (0.78–0.99) 0.88 (0.77–1.00) 0.85 (0.76–0.95) 0.80 (0.71–0.90) 0.90 (0.80–1.01) 0.005
Model 4 1 (reference) 0.91 (0.82–1.01) 0.84 (0.74–0.96) 0.86 (0.75–0.99) 0.83 (0.75–0.93) 0.79 (0.70–0.88) 0.89 (0.78–1.01) 0.009
Numbers in the table are prevalence ratio (95% confidence interval). Model 1: adjustment for age, race/ethnicity, and sex. Model 2: adjustment for the variables 
in Model 1 plus risk factors for incident hypertension, cardiovascular disease, and target-organ damage (ie, heart rate, total cholesterol, high-density lipoprotein 
cholesterol, diabetes mellitus, estimated glomerular filtration rate, urinary albumin-to-creatinine ratio, and 10-y predicted atherosclerotic cardiovascular disease risk). 
Model 3: adjustment for the variables in Model 1 plus modifiable lifestyle risk factors (ie, body mass index, smoking status, physical activity level, alcohol consumption, 
and Dietary Approaches to Stop Hypertension adherence). Model 4: adjustment for the variables in Model 1, Model 2, and Model 3. Normal blood pressure: systolic blood 
pressure <120 mm Hg and diastolic blood pressure <80 mm Hg without antihypertensive medication use. Prehypertension: systolic blood pressure 120–139 mm Hg 
with diastolic blood pressure <90 mm Hg or diastolic blood pressure 80–89 mm Hg with systolic blood pressure <140 mm Hg without antihypertensive medication use. 
Hypertension: systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or antihypertensive medication use.
*Statistical significance of the trend in the change of the prevalence ratio over calendar period.
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Table 2. Risk Factors for Incident Hypertension, Cardiovascular Disease, and Target-Organ Damage Among US Adults ≥20 Y of Age 
With Prehypertension by Calendar Year
Risk Factor 
Risk Factors for Incident Hypertension, Cardiovascular Disease, and Target-Organ Damage
National Health and Nutrition Examination Survey Calendar Year
P Trend*1999–2000 2001–2002 2003–2004 2005–2006 2007–2008 2009–2010 2011–2012
Mean heart rate, bpm 71.3 (70.5–72.1) 72.9 (71.8–74.0) 73.2 (71.8–74.6) 72.6 (71.5–73.6) 74.2 (73.0–75.4) 73.0 (72.1–73.9) 73.5 (72.3–74.7) 0.003
Systolic blood pressure, 
mm Hg
0.219
  120–129 70.0 (64.2–75.8) 66.2 (62.9–69.4) 66.7 (62.8–70.7) 66.3 (63.1–69.5) 71.8 (69.2–74.5) 71.2 (68.2–74.3) 68.7 (64.5–72.8)
  130–139 30.0 (24.2–35.8) 33.8 (30.6–37.1) 33.3 (29.3–37.2) 33.7 (30.5–36.9) 28.2 (25.5–30.8) 28.8 (25.7–31.8) 31.3 (27.2–35.5)
Diastolic blood pressure, 
mm Hg
0.715
  80–84 73.3 (66.9–79.7) 70.2 (65.5–75) 67.9 (57.8–78.0) 70.4 (63.8–77.0) 78.9 (75.3–82.6) 71.0 (64.9–77.2) 67.6 (60.6–74.5)
  85–89 26.7 (20.3–33.1) 29.8 (25.0–34.5) 32.1 (22.0–42.2) 29.6 (23.0–36.2) 21.1 (17.4–24.7) 29.0 (22.8–35.1) 32.4 (25.5–39.4)
Total cholesterol 0.018
  Normal (<200 mg/dL) 44.7 (40.4–49.0) 47.1 (44.9–49.4) 47.7 (44.0–51.3) 49.6 (46.0–53.2) 49.0 (44.3–53.8) 50.2 (46.5–53.8) 48.9 (44.7–53.0)
  Borderline elevated 
(200–239 mg/dL)
37.0 (32.0–41.9) 34.2 (30.8–37.5) 32.3 (28.4–36.1) 32.7 (29.1–36.4) 32.0 (27.1–36.9) 34.2 (31.7–36.7) 36.4 (33.2–39.7)
  Elevated  
(≥240 mg/dL)
18.4 (13.7–23) 18.7 (15.0–22.4) 20.0 (15.5–24.6) 17.7 (14.6–20.7) 19.0 (14.6–23.4) 15.6 (12.9–18.4) 14.7 (11.2–18.3)
High-density lipoprotein 
cholesterol
0.220
  Normal (men, ≥40; 
women, ≥50; mg/dL)
63.8 (60.0–67.7) 69.5 (65.8–73.3) 70.1 (64.7–75.5) 72.8 (69.7–75.9) 65.2 (59.5–70.9) 68.6 (65.6–71.5) 71.7 (65.4–78.1)
  Low (men, <40; 
women, <50; mg/dL)
36.2 (32.3–40.0) 30.5 (26.7–34.2) 29.9 (24.5–35.3) 27.2 (24.1–30.3) 34.8 (29.1–40.5) 31.4 (28.5–34.4) 28.3 (21.9–34.6)
C-reactive protein 0.162
  Normal (<1 mg/L) 90.2 (87.4–93.1) 91.8 (89.4–94.2) 91.6 (89.1–94.2) 90.0 (87.6–92.4) 91.9 (90.0–93.7) 92.9 (91.2–94.5) NR  
  Borderline elevated 
(1–2.9 mg/L)
8.8 (5.4–12.3) 7 (4.5–9.4) 6.7 (4.2–9.2) 8.2 (5.9–10.5) 7.3 (5.8–8.7) 6.2 (4.8–7.6) NR
  Elevated (≥3 mg/L) 0.9 (0.0–1.8) 1.2 (0.5–2.0) 1.7 (0.6–2.8) 1.8 (0.7–2.8) 0.9 (0.3–1.4) 0.9 (0.4–1.5) NR  
Diabetes mellitus status <0.001
  No diabetes mellitus 84.4 (80.4–88.4) 82.1 (79.0–85.1) 81.9 (78.9–84.9) 79.3 (74.4–84.1) 70.5 (65.7–75.3) 69.4 (66.0–72.8) 69.9 (67.8–72.0)
  Prediabetes 9.6 (7.1–12.1) 11.2 (8.4–14.0) 12.9 (10.3–15.6) 13.8 (9.9–17.7) 21.3 (17.0–25.5) 24.1 (21.1–27.0) 21.6 (19.6–23.5)
  Diabetes mellitus 6.0 (4.0–7.9) 6.7 (4.8–8.7) 5.2 (3.9–6.4) 7.0 (4.7–9.2) 8.3 (6.6–9.9) 6.5 (5.2–7.8) 8.5 (7.0–10.0)
Estimated glomerular 
filtration rate
0.525
  Normal (≥60 mL/
min/1.73 m2)
97.2 (96.2–98.2) 97.5 (96.3–98.6) 96.9 (95.7–98.0) 96.4 (94.9–97.8) 96.8 (95.4–98.2) 97.4 (96.2–98.6) 97.5 (96.5–98.5)
  Reduced (<60 mL/
min/1.73 m2)
2.8 (1.8–3.8) 2.5 (1.4–3.7) 3.1 (2.0–4.3) 3.6 (2.2–5.1) 3.2 (1.8–4.6) 2.6 (1.4–3.8) 2.5 (1.5–3.5)
Urinary albumin-to-
creatinine ratio
0.938
  Normal (≤30 mg/g) 92.6 (90.4–94.8) 92.7 (90.7–94.7) 93.3 (91.1–95.5) 93.9 (92–95.7) 91.6 (89.2–94) 95.0 (93.5–96.4) 91.9 (89.5–94.4)
  Elevated (>30 mg/g) 7.4 (5.2–9.6) 7.3 (5.3–9.3) 6.7 (4.5–8.9) 6.1 (4.3–8) 8.4 (6–10.8) 5.0 (3.6–6.5) 8.1 (5.6–10.5)
10-y predicted ASCVD 
risk, %
0.343
  <7.5 64.9 (59.7–70.1) 63.1 (58.2–68.1) 64.2 (60.8–67.6) 65.5 (59.3–71.7) 61.6 (58.2–65) 66.7 (64.5–68.9) 66.2 (60.3–72.1)
  ≥7.5 35.1 (29.9–40.3) 36.9 (31.9–41.8) 35.8 (32.4–39.2) 34.5 (28.3–40.7) 38.4 (35.0–41.8) 33.3 (31.1–35.5) 33.8 (27.9–39.7)
Numbers in the table are mean (95% confidence interval) or percentage (95% confidence interval). Standard international system conversion factors: to convert mg/
dL to mmol/L, multiply values by 0.0259, and to convert mg/L to mmol/L, multiply values by 5.581. ASCVD indicates atherosclerotic cardiovascular disease; and NR, not 
reported because of data not being available at the time of analyses. 
*Statistical significance of the trend in the change of the prevalence over calendar period.
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incident hypertension, target-organ damage and CVD, and 
modifiable lifestyle risk factors in adults with prehypertension 
since the JNC7 characterized individuals with prehyperten-
sion as having an increased risk for transitioning to hyper-
tension. Population-level approaches that improve CVD and 
lifestyle risk factors may help lower the risk for hypertension 
among US adults with prehypertension.
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Table 3. Modifiable Lifestyle Risk Factors for Incident Hypertension Among US Adults ≥20 Y of Age With Prehypertension by 
Calendar Year
Modifiable 
Lifestyle Risk 
Factor
Modifiable Lifestyle Risk Factors for Incident Hypertension
National Health and Nutrition Examination Survey Calendar Year
P Trend*1999–2000 2001–2002 2003–2004 2005–2006 2007–2008 2009–2010 2011–2012
Body mass index 
categories
<0.001
  Normal (<25 
kg/m2)
35.8 (32.2–39.5) 31.7 (28.8–34.6) 27.6 (23.2–32.0) 28.8 (23.5–31.7) 28.4 (24.1–32.8) 26.2 (21.4–31.0) 27.5 (22.9–32.2)
  Overweight 
(25–30 kg/m2)
33.5 (29.4–37.7) 37.9 (34.3–41.5) 39.3 (34.2–44.4) 32.7 (30.3–35.1) 37.4 (34.4–40.4) 34.3 (29.9–38.7) 37.3 (31.2–43.4)
  Obese (≥30 
kg/m2)
30.6 (26.4–34.8) 30.3 (25.7–35.0) 33.1 (29.2–37.0) 38.4 (34.4–42.5) 34.2 (30.2–38.2) 39.5 (35.5–43.4) 35.2 (31.7–38.7)
Smoking status 0.097
  Current 25.9 (22.5–29.3) 26.8 (23.6–29.9) 27.5 (24.6–30.5) 24.7 (21.2–28.3) 25.7 (21.7–29.8) 21.4 (19.1–23.6) 23.2 (20.1–26.2)
  Former/never 74.1 (70.7–77.5) 73.2 (70.1–76.4) 72.5 (69.5–75.4) 75.3 (71.7–78.8) 74.3 (70.2–78.3) 78.6 (76.4–80.9) 76.8 (73.8–79.9)
Physical activity 
(leisure time)
0.127
  Ideal 38.1 (33.5–42.7) 44.8 (41.3–48.4) 39.8 (37.1–42.4) 41.4 (38.0–44.8) 35.7 (30.5–40.9) 37.9 (33.7–42.1) 39.6 (34.6–44.6)
  Intermediate 21.9 (17.0–26.9) 24.1 (21.6–26.7) 30.6 (27.6–33.6) 26.5 (22.3–30.8) 20.0 (17.0–23.0) 16.3 (14.3–18.2) 16.5 (14.1–18.8)
  Poor 40.0 (35.9–44.1) 31.0 (27.1–34.9) 29.6 (26.3–33.9) 32.0 (27.0–37.1) 44.3 (38.1–50.5) 45.8 (41.1–50.5) 43.9 (38.7–49.1)
Alcohol 
consumption†
0.393
  None 11.8 (8.2–15.4) 14.6 (7.8–21.4) 11.5 (9.0–14.0) 10.7 (5.8–15.7) 11.6 (9.4–13.8) 11.1 (8.5–13.6) 10.6 (7.8–13.4)
  Moderate 76.6 (73.3–80.0) 72.9 (66.4–79.3) 77.5 (74.8–80.2) 76.9 (71.5–82.2) 75.2 (72.5–77.8) 77.1 (73.3–80.8) 77.0 (73.1–80.9)
  Heavy 11.6 (9.2–14.0) 12.5 (10.9–14.1) 11.0 (8.3–13.7) 12.4 (9.8–15.0) 13.2 (10.9–15.6) 11.9 (9.8–14.0) 12.4 (8.8–16.0)
DASH diet 
adherence 
categories
0.007
  Quartile 1 
(low, less 
healthy)
38.2 (33.7–42.8) 37.7 (32.8–42.6) 31.7 (27.8–35.5) 43.6 (38.0–49.1) 39.0 (34.0–44.0) 43.7 (39.8–47.7) 41.6 (35.1–48.1)
  Quartile 2 25.3 (21.6–29.0) 23.3 (20.4–26.2) 24.2 (21.1–27.4) 28.2 (24.6–31.8) 28.5 (25.0–31.8) 25.8 (22.0–29.5) 26.5 (22.2–30.8)
  Quartile 3 18.1 (15.0–21.1) 19.8 (16.6–23.0) 24.9 (21.5–28.3) 17.1 (14.8–19.4) 18.7 (16.1–21.2) 19.5 (17.3–21.8) 20.0 (16.8–23.1)
  Quartile 
4 (high, 
healthier)
18.4 (16.2–20.5) 19.3 (16.9–21.6) 19.2 (17.0–21.3) 11.1 (7.9–14.4) 13.9 (10.9–16.8) 10.9 (8.9–13.0) 11.9 (8.5–15.4)
Numbers in the table are percentage (95% confidence interval).  The cut points for the DASH diet scores used to group participants into quartiles based on the 
distribution among US adults ≥20 y old were (quartile 1 [least healthy] to quartile 4 [healthiest]): <25, 25 to <28, 28 to <31 and ≥31). DASH indicates Dietary Approaches 
to Stop Hypertension. 
 *Statistical significance of the trend in the change of the prevalence during calendar period. 
†Alcohol consumption: none, 0 drinks per wk; moderate, >0 to <8 drinks per wk for women and >0 and <15 drinks per wk for men; heavy, ≥8 drinks per wk for 
women and ≥15 drinks per wk for men.
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What Is New?
•	Between 1999–2000 and 2011–2012, the age-adjusted prevalence of 
prehypertension decreased.
•	 In 2011–2012, after adjustment for age, 28.2% of US adults had pre-
hypertension.
•	Among adults with prehypertension, prediabetes, diabetes mellitus, 
overweight and obesity increased and Dietary Approaches to Stop Hy-
pertension adherence decreased.
•	Also, there was a nonstatistically significant increase in no physical ac-
tivity each week, nonstatistically significant decrease in current smoking 
and alcohol consumption did not change among adults with prehyper-
tension.
What Is Relevant?
•	Population-level approaches directed at adults with prehypertension 
should focus on improving risk factors to prevent hypertension and car-
diovascular disease.
Summary
The prevalence of prehypertension is high among US adults and 
many adults with prehypertension have poor levels of many modifi-
able risk factors for incident hypertension and cardiovascular dis-
ease.
Novelty and Significance
